Key statistics
On Friday, Biomea Fusion Inc (BMEA:NSQ) closed at 6.35, 75.90% above the 52 week low of 3.61 set on Jun 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.36 |
---|---|
High | 6.74 |
Low | 6.23 |
Bid | 6.34 |
Offer | 6.36 |
Previous close | 6.38 |
Average volume | 647.65k |
---|---|
Shares outstanding | 36.24m |
Free float | 27.17m |
P/E (TTM) | -- |
Market cap | 231.20m USD |
EPS (TTM) | -4.00 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 20:47 GMT.
More ▼
- Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
- Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
- Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
- Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
- Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy
- Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
- Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
- FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
- Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
More ▼